专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20030153759A1 1-Glyoxlylamide indolizines for treating cancer 失效
标题翻译： 1-乙氧基酰胺中氮茚类药物用于治疗癌症
公开(公告)号：US20030153759A1
公开(公告)日：2003-08-14
申请号：US10244088
申请日：2002-09-13
申请人： SBR Pharmaceuticals Corp.
发明人： Keizo Koya , Lijun Sun , Mitsunori Ono , Weiwen Ying , Hao Li
IPC分类号： C07D455/02 , A61K031/506 , A61K031/4745
CPC分类号： C07D471/04
摘要： Disclosed is a compound represented by Structural Formula (I): 1 Ring A is substituted or unsubstituted and optionally fused to an aryl group. Z1 and Z2 are independently nullO, nullS, nullNnullOR12 or nullNR12 R1 and R2 are independently nullH, an aliphatic group, a substituted aliphatic group, an unsubstituted non-aromatic heterocylic group, a substituted non-aromatic heterocylic group, an aryl group or a substituted aryl group, provided that R1 and R2 are not both nullH. Alternatively, nullNR1R2, taken together, is a substituted or unsubstituted non-aromatic nitrogen-containing heterocyclic group or a substituted or unsubstituted nitrogen-containing heteroaryl group. R3 is a substituted or unsubstituted aryl group or a substituted or unsubstituted aliphatic group. X is a covalent bond, nullC(R4R5)null, nullN(R4)null, nullOnull, nullSnull, nullS(O)null, nullS(O)2null, nullC(nullO)null, nullC(nullO)nullN(R4)-, or nullN(R4)nullC(nullO)null. R4 and R5 are independently nullH or a substituted or unsubstituted aliphatic group. R12 is nullH or a substituted or unsubstituted alkyl group.
摘要翻译：公开了由结构式（I）表示的化合物：环A是取代或未取代的且任选地与芳基稠合。 Z 1和Z 2独立地为= O，= S，= N-OR 12或= NR 12 R 1和R 2独立地为-H，脂族基团，取代的脂族基团，未取代的非芳族杂环基团，取代的非芳族杂环基团，芳基或取代的芳基，条件是R1和R2不同时为-H。或者，-NR 1 R 2一起是取代或未取代的非芳族含氮杂环基或取代或未取代的含氮杂芳基。 R3是取代或未取代的芳基或取代或未取代的脂族基团。 X是共价键，-C（R4R5） - ， - N（R4） - ， - O - ， - S - ， - S（O） - ， - S（O），-C（= O）-N（R 4） - 或-N（R 4）-C（= O） - 。 R 4和R 5独立地为-H或取代或未取代的脂族基团。 R 12是-H或取代或未取代的烷基。

2. 发明申请

US20030096836A1 2-Aroylimidazole compounds for treating cancer 失效
标题翻译：用于治疗癌症的2-芳酰咪唑化合物
公开(公告)号：US20030096836A1
公开(公告)日：2003-05-22
申请号：US10233371
申请日：2002-08-29
申请人： SBR Pharmaceuticals Corp.
发明人： Keizo Koya , Lijun Sun , Mitsunori Ono , David James , Weiwen Ying , Shoujun Chen
IPC分类号： C07D471/02 , A61K031/4745 , A61K031/4184 , A61K031/4178
CPC分类号： C07D231/12 , C07D233/56 , C07D249/08 , C07D401/14 , C07D403/04 , C07D403/14 , C07D413/14 , C07D471/04
摘要： Disclosed is a compound represented by Structural Formula (I): 1 R1 is a substituted or unsubstituted 2-imidazolyl group which is optionally fused to a substituted or unsubstituted aryl group. Z1 is nullO, nullS, nullNOR11, or nullNR11. R is represented by a Structural Formula selected from (II)-(VII): 2 The variables in Structural Formulas (II)-(VII) are described below.
摘要翻译：公开了由结构式（I）表示的化合物：R 1是任选地与取代或未取代的芳基稠合的取代或未取代的2-咪唑基。 Z1是= O，= S，= NOR11或= NR11。 R由选自（II） - （VII）的结构式表示：结构式（II） - （VII）中的变量如下所述。

3. 发明申请

US20030092751A1 3-glyoxlylamideindoles for treating cancer 失效
标题翻译：用于治疗癌症的3-乙醛酰胺二吲哚
公开(公告)号：US20030092751A1
公开(公告)日：2003-05-15
申请号：US10232394
申请日：2002-08-29
申请人： SBR Pharmaceuticals Corp.
发明人： Keizo Koya , Lijun Sun , Mitsunori Ono , Guiqing Liang , David James , Hao Li , Zhi-Qiang Xia
IPC分类号： A61K031/427 , A61K031/422 , A61K031/4178 , A61K031/4196 , A61K031/416 , A61K031/404 , C07D417/02 , C07D413/02 , C07D43/02
CPC分类号： C07D249/08 , C07D209/12 , C07D209/18 , C07D231/12 , C07D233/56 , C07D401/12 , C07D403/12 , C07D405/14 , C07D413/12 , C07D417/12
摘要： Disclosed is an anti-cancer compound represented by Structural Formula (I): 1 The variables in Structural Formula (I) are described hereinbelow. Also disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Structural Formula (I) (preferably an effective amount). Also disclosed is a method of treating a subject with cancer by administering to the subject an effective amount of a compound represented by Structural Formula (I).
摘要翻译：公开了由结构式（I）表示的抗癌化合物：结构式（I）中的变量如下所述。还公开了包含药学上可接受的载体或稀释剂和由结构式（I）表示的化合物（优选有效量））的药物组合物。还公开了通过向受试者施用有效量的由结构式（I）表示的化合物来治疗患有癌症的受试者的方法。

4. 发明申请

WO2003022280A2 3-GLYOXLYLAMIDEINDOLES FOR TREATING CANCER 审中-公开
标题翻译： 3-GLYOXLYLAMIDEINDOLES用于治疗癌症
公开(公告)号：WO2003022280A2
公开(公告)日：2003-03-20
申请号：PCT/US2002/027513
申请日：2002-08-28
申请人： SBR PHARMACEUTICALS CORP. , KOYA, Keizo , SUN, Lijun , ONO, Mitsunori , LIANG, Guiqing , JAMES, David , LI, Hao , XIA, Zhi-Qiang
发明人： KOYA, Keizo , SUN, Lijun , ONO, Mitsunori , LIANG, Guiqing , JAMES, David , LI, Hao , XIA, Zhi-Qiang
IPC分类号： A61K31/47
CPC分类号： C07D249/08 , C07D209/12 , C07D209/18 , C07D231/12 , C07D233/56 , C07D401/12 , C07D403/12 , C07D405/14 , C07D413/12 , C07D417/12
摘要： Disclosed is an anti-cancer compound represented by Structural Formula (I). The variables in Structural Formula (I) are described herein. Also disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Structural Formula (I) (preferablyan effective amount). Also disclosed is a method of treating a subject with cancer by administering to the subject an effective amount of a compound represented by Structural Formula (I).
摘要翻译：公开了由结构式（I）表示的抗癌化合物。本文描述了结构式（I）中的变量。还公开了包含药学上可接受的载体或稀释剂和由结构式（I）表示的化合物（优选有效量））的药物组合物。还公开了通过向受试者施用有效量的由结构式（I）表示的化合物来治疗患有癌症的受试者的方法。

5. 发明申请

WO2003006429A1 SYNTHESIS OF TAXOL ENHANCERS 审中-公开
标题翻译： TAXOL增强剂的合成
公开(公告)号：WO2003006429A1
公开(公告)日：2003-01-23
申请号：PCT/US2002/021716
申请日：2002-07-10
申请人： SBR PHARMACEUTICALS CORP. , CHEN, Shoujun , SUN, Lijun , XIA, Zhi-Qiang , KOYA, Keizo , ONO, Mitsunori
发明人： CHEN, Shoujun , SUN, Lijun , XIA, Zhi-Qiang , KOYA, Keizo , ONO, Mitsunori
IPC分类号： C07C327/56
CPC分类号： C07D213/77 , C07C327/56 , C07C2601/14 , C07D209/42 , C07D209/44 , C07D213/83 , C07D261/18 , C07D307/54 , C07D333/38 , Y02P20/55
摘要： Disclosed is a method of preparing a thiohydrazide compound a formula (II) from a hydrazide starting compound of formula (I). The method comprises reacting the starting compound of formula (I) with a thionylating reagent. The thiohydrazide of formula (II) can be reacted with compounds of the formula Z-C(O)-Y-C(O)-z or HO-C(O)-Y-C(O)-OH and a carboxylic acid activating agent to produce compound of formula III which enhance the anti-cancer activity of taxol and analogs thereof. The variables R1, R2,R5, R10, Y and Z are as defined in the claims.
摘要翻译：公开了由式（I）的酰肼起始化合物制备式（II）的硫代酰肼化合物的方法。该方法包括使式（I）的起始化合物与亚硫酰化试剂反应。可以使式（II）的硫代酰肼与式ZC（O）-YC（O）-z或HO-C（O）-YC（O）-OH的化合物和羧酸活化剂反应，生成化合物式III，其增强了紫杉醇及其类似物的抗癌活性。变量R1，R2，R5，R10，Y和Z如权利要求中所定义。

6. 发明申请

WO03022280A3 3-GLYOXLYLAMIDEINDOLES FOR TREATING CANCER 审中-公开
标题翻译：用于治疗癌症的3-甘油酰胺醇
公开(公告)号：WO03022280A3
公开(公告)日：2003-05-22
申请号：PCT/US0227513
申请日：2002-08-28
申请人： SBR PHARMACEUTICALS CORP , KOYA KEIZO , SUN LIJUN , ONO MITSUNORI , LIANG GUIQING , JAMES DAVID , LI HAO , XIA ZHI-QIANG
发明人： KOYA KEIZO , SUN LIJUN , ONO MITSUNORI , LIANG GUIQING , JAMES DAVID , LI HAO , XIA ZHI-QIANG
IPC分类号： A61K31/405 , A61K31/4155 , A61K31/4196 , A61K31/422 , A61K31/423 , A61K31/425 , A61K31/433 , A61K31/4439 , A61K31/4709 , A61P35/00 , C07D209/12 , C07D209/14 , C07D209/18 , C07D401/12 , C07D403/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D521/00 , A61K31/47 , A61K31/40 , A61K31/41 , A61K31/42 , A61K31/44
CPC分类号： C07D249/08 , C07D209/12 , C07D209/18 , C07D231/12 , C07D233/56 , C07D401/12 , C07D403/12 , C07D405/14 , C07D413/12 , C07D417/12
摘要： Disclosed is an anti-cancer compound represented by Structural Formula (I). The variables in Structural Formula (I) are described herein. Also disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Structural Formula (I) (preferablyan effective amount). Also disclosed is a method of treating a subject with cancer by administering to the subject an effective amount of a compound represented by Structural Formula (I).
摘要翻译：公开了由结构式（I）表示的抗癌化合物。本文描述了结构式（I）中的变量。还公开了包含药学上可接受的载体或稀释剂和由结构式（I）表示的化合物（优选有效量）的药物组合物。还公开了通过向受试者施用有效量的由结构式（I）表示的化合物来治疗患有癌症的受试者的方法。

7. 发明申请

WO2003006428A1 TAXOL ENHANCER COMPOUNDS 审中-公开
标题翻译： TAXOL增强剂化合物
公开(公告)号：WO2003006428A1
公开(公告)日：2003-01-23
申请号：PCT/US2002/021714
申请日：2002-07-10
申请人： SBR PHARMACEUTICALS CORP. , KOYA, Keizo , SUN, Lijun , CHEN, Shoujun , TATSUTA, Noriaki , WU, Yaming , ONO, Mitsunori , XIA, Zhi-Qiang
发明人： KOYA, Keizo , SUN, Lijun , CHEN, Shoujun , TATSUTA, Noriaki , WU, Yaming , ONO, Mitsunori , XIA, Zhi-Qiang
IPC分类号： C07C327/56
CPC分类号： C07D307/68 , A45D2008/006 , A61K31/337 , A61K31/505 , A61K31/53 , A61K31/5377 , A61K47/58 , C07C327/56 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D209/42 , C07D209/44 , C07D213/83 , C07D261/18 , C07D333/38 , C07D333/68
摘要： One embodiment of the present invention is a compound represented by Structural Formula (I) wherein Y is a covalent bond of a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or -C(R 7 R 8 )-. R 1 is an aliphatic group, a substituted aliphatic group, a non-aromatic hetereocyclic group, or a substituted non-aromatic hetereocyclic group, R 2 -R 4 are independently -H, an aliphatic group, a substituted aliphatic group, a non-aromatic hetereocyclic group, a substituted non-aromatic hetereocyclic group, an aryl group or a substituted aryl group, or R 1 and R 3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R 2 and R 4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R 5 -R 6 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R 7 and R 8 are each independently -H, an aliphatic or substituted aliphatic group, or R 7 is -H and R 8 is a substituted or unsubstituted aryl group, or, R 7 and R 8 , taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is =0 or =S. Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent.
摘要翻译：本发明的一个实施方案是由结构式（I）表示的化合物，其中Y是取代或未取代的直链烃基的共价键。此外，Y与它所键合的两个> C = Z基团一起是取代或未取代的芳族基团。优选Y为共价键或-C（R 7 R 8） - 。 R1是脂肪族基团，取代脂肪族基团，非芳香族杂环基团或取代的非芳香族杂环基团，R2-R4独立地是-H，脂肪族基团，取代的脂肪族基团，非芳香族的杂环基团，取代的非芳香族杂环基团，芳基或取代的芳基，或者R 1和R 3与它们所键合的碳原子和氮原子一起，和/或R 2和R 4与碳和氮原子一起形成与芳环稠合的非芳族杂环。 R5-R6独立地是-H，脂族基团，取代的脂族基团，芳基或取代的芳基。 R 7和R 8各自独立地为-H，脂族或取代的脂族基团，或者R 7为-H且R 8为取代或未取代的芳基，或者R 7和R 8一起为C 2 -C 6取代或未取代的亚烷基。 Z = 0或= S。还公开了包含本发明化合物和药学上可接受的载体或稀释剂的药物组合物。

8. 发明申请

WO03022274A3 2-AROYLIMIDAZOLE COMPOUNDS FOR TREATING CANCER 审中-公开
标题翻译： 2-AROYLIMIDAZOLE化合物治疗癌症
公开(公告)号：WO03022274A3
公开(公告)日：2003-07-10
申请号：PCT/US0227514
申请日：2002-08-28
申请人： SBR PHARMACEUTICALS CORP , KOYA KEIZO , SUN LIJUN , ONO MITSUNORI , JAMES DAVID , YING WIEWEN , CHEN SHOUJUN
发明人： KOYA KEIZO , SUN LIJUN , ONO MITSUNORI , JAMES DAVID , YING WIEWEN , CHEN SHOUJUN
IPC分类号： C07D473/16 , A61K31/4178 , A61K31/422 , A61K31/437 , A61K31/4439 , A61K31/5377 , A61P35/00 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/14 , C07D413/14 , C07D471/04 , C07D519/00 , C07D521/00 , A61K31/42 , A61K31/415 , A61K31/435 , A61K31/44
CPC分类号： C07D231/12 , C07D233/56 , C07D249/08 , C07D401/14 , C07D403/04 , C07D403/14 , C07D413/14 , C07D471/04
摘要： Disclosed is a compound represented by Structural Formula (I). R1 is a substituted or unsubstituted 2-imidazolyl group which is optionally fused to a substituted or unsubstituted aryl group. Zl is =0, =S, =NOR11, or =NR11. R is represented by a Structural Formula selected from formulas (II)-(VII). The variables in Structural Formulas (II)-(VII) are described below. These 2-aroylimidazole compounds are cytotoxic against cancer cells, including multi-drug resistant cancer cells, from a number of different tissue types.
摘要翻译：公开了由结构式（I）表示的化合物。 R1是取代或未取代的2-咪唑基，其任选地与取代或未取代的芳基稠合。 Zl = 0，= S，= NOR11或= NR11。 R由选自式（II） - （VII）的结构式表示。结构式（II） - （VII）中的变量如下所述。这些2-芳酰基咪唑化合物对来自多种不同组织类型的癌细胞（包括多药耐药性癌细胞）是细胞毒性的。

9. 发明申请

WO2003022846A1 1-GLYOXLYLAMIDE INDOLIZINES FOR TREATING CANCER 审中-公开
标题翻译： 1-GLYOXLYLAMIDE INDOLIZINES FOR TRANTING CANCER
公开(公告)号：WO2003022846A1
公开(公告)日：2003-03-20
申请号：PCT/US2002/029154
申请日：2002-09-13
申请人： SBR PHARMACEUTICALS CORP. , KOYA, Keizo , SUN, Lijun , ONO, Mitsunori , YING, Weiwen , LI, Hao
发明人： KOYA, Keizo , SUN, Lijun , ONO, Mitsunori , YING, Weiwen , LI, Hao
IPC分类号： C07D471/04
CPC分类号： C07D471/04
摘要： Disclosed is a compound represented by Structural Fonnula (I): Ring A is substituted or unsubstituted and optionally fused to an aryl group. Z 1 and Z 2 are independently =0, =S, =N-OR 12 or =NR 12 ; R 1 and R 2 are independently -H, an aliphatic group, a substituted aliphatic group, an unsubstituted non-aromatic heterocylic group, a substituted non-aromatic heterocylic group, an aryl group or a substituted aryl group, provided that R 1 and R 2 are not both -H. Alternatively, -NR 1 R 2 , taken together, is a substituted or unsubstituted non-aromatic nitrogen-containing heterocyclic group or a substituted or unsubstituted nitrogen-containing heteroaryl group. R 3 is a substituted or unsubstituted aryl group or a substituted or unsubstituted aliphatic group. X is a covalent bond, -C(R 4 R 5 )-, -N(R 4 )-, -0-, -S-, -S(O)-, -S(0) 2 -, -C(=O)-, -C(=0)-N(R 4 )-, or N(R 4 )-C(=O)-. R 4 and R 5 are independently -H or a substituted or unsubstituted aliphatic group. R 12 is -H or a substituted or unsubstituted alkyl group.
摘要翻译：公开了由结构式（I）表示的化合物：环A是取代或未取代的，并任选地与芳基稠合。 Z> 1 <和Z> 2 <独立地= 0，= S，= N-OR> 12 <或= NR> 12 < R 1和R 2独立地是-H，脂族基团，取代的脂族基团，未取代的非芳族杂环基团，取代的非芳族杂环基团，芳基或取代的芳基，条件是 R＆gt; 1＆lt;和＆lt; 2＆gt;不同于-H。或者，-NR> 1 2一起是取代或未取代的非芳族含氮杂环基或取代或未取代的含氮杂芳基。 R 3是取代或未取代的芳基或取代或未取代的脂族基。 X是共价键，-C（R 5）5 - ， - （R 4） - ， - O - ， - S - ， - S（O） - ， - S（O） > - ， - （= O） - ， - （= O）-N（R 4） - 或N（R 4））C（= O） - 。 R 4和R 5独立地是-H或取代或未取代的脂族基团。 R 12为-H或取代或未取代的烷基。

10. 发明申请

WO2003022274A2 2-AROYLIMIDAZOLE COMPOUNDS FOR TREATING CANCER 审中-公开
标题翻译： 2-AROYLIMIDAZOLE化合物治疗癌症
公开(公告)号：WO2003022274A2
公开(公告)日：2003-03-20
申请号：PCT/US2002/027514
申请日：2002-08-28
申请人： SBR PHARMACEUTICALS CORP. , KOYA, Keizo , SUN, Lijun , ONO, Mitsunori , JAMES, David , YING, Wiewen , CHEN, Shoujun
发明人： KOYA, Keizo , SUN, Lijun , ONO, Mitsunori , JAMES, David , YING, Wiewen , CHEN, Shoujun
IPC分类号： A61K31/42
CPC分类号： C07D231/12 , C07D233/56 , C07D249/08 , C07D401/14 , C07D403/04 , C07D403/14 , C07D413/14 , C07D471/04
摘要： Disclosed is a compound represented by Structural Formula (I). R 1 is a substituted or unsubstituted 2-imidazolyl group which is optionally fused to a substituted or unsubstituted aryl group. Z l is =0, =S, =NOR 11 , or =NR 11 . R is represented by a Structural Formula selected from formulas (II), (III), (IV), (V), (VI), (VII). The variables in Structural Formulas (II)-(VII) are described below.
摘要翻译：公开了由结构式（I）表示的化合物。 R1是取代或未取代的2-咪唑基，其任选地与取代或未取代的芳基稠合。 Zl = 0，= S，= NOR11或= NR11。 R由选自式（II），（III），（IV），（V），（VI），（VII））的结构式表示。结构式（II） - （VII）中的变量如下所述。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式